bioTheranostics, Inc., a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, today announced clinical study findings that link CancerTYPE ID® molecular testing with improved patient outcome. Patients in which CancerTYPE ID predicted a colorectal site of origin that subsequently received site-specific therapy had a median survival three times that of what has been reported in patients treated empirically for cancer of unknown primary (CUP). These results make CancerTYPE ID the only marketed molecular cancer classifier to demonstrate therapeutic response and patient benefit based on molecular tumor profiling.
Nachrichten
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
04 Mai, 2022Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...
bioMérieux Expands its Infectious Disease Offering with Acquisition of ARGENE, Specialized in Molecular Diagnostics for Immunocompromised Patients
19 Juli, 2011
bioMérieux, a world leader in the field of in vitro diagnostics, announced that it has acquired ARGENE, a French company specialized in molecular diagnostics. This acquisition is bioMérieux’s tenth in the last five years.
World HAI Forum: Global Call to Action to Fight Antibiotic Resistance
30 Juni, 2011
Over 70 international experts in medicine, infectious diseases, microbiology and epidemiology, from every continent, gathered at the Fondation Mérieux’s Conference Center for the third edition of the World HAI Forum on healthcare-associated infections, a bioMérieux initiative. Forum participants call upon national and international health authorities and policy makers, the medical and veterinary communities, Industry, and the general public to take action to avoid an impending public health catastrophe caused by the emergence and spread of bacteria that are resistant to all antibiotics.
bioMérieux and Labor Berlin (Charité Vivantes GmbH) to Establish Center of Excellence in Laboratory Diagnostics
05 Mai, 2011
Labor Berlin and bioMérieux announce the signature of an agreement to create a Center of Excellence for microbiology and enhanced laboratory automation. The center will be located at Europe’s largest hospital laboratory, serving more than 8,000 in-house patients in Berlin and handling over 23 million patient analyses a year.